Effect of Preloading With High Dose of Rosuvastatin on Serum Levels of Inflammatory Markers After Percutaneous Coronary Intervention

Author(s):Show less -

Slhessarenko, Juliano R. ^[1] ; Hirata, Mario ^{[1, 2]} ; Sousa, Amanda ^[1] ; Bastos, Gisele M. ^[1] ; Higa, Elisa M. S. ^[3] ; Mouro, Margareth G. ^[3] ; Sobrera, Guilherme C. ^[2] ; Slhessarenko, Renata D. ^[4] ; Viana, Renata ^[1] ; Abizaid, Alexandre ^[1] ; Costa Jr, J. Ribamar

Affiliation

^[1] Inst Dante Pazzanese Cardiol, Sao Paulo - Brazil

^[2] Sao Paulo Univ USP, Sao Paulo - Brazil

^[3] Fed Univ Sao Paulo UNIFESP, Sao Paulo - Brazil

^[4] Univ Fed Mato Grosso, Cuiaba - Brazil

• Document type: Journal article
• Source: JOURNAL OF INVASIVE CARDIOLOGY; v. 32, n. 9, p. 335+, SEP 2020.
• Web of Science Citations: 0

Abstract

Objectives. We sought to assess the effects of a high loading dose of rosuvastatin (40 mg) on acute inflammatory response after coronary stenting. Methods. Patients with stable coronary disease without statin use (>= 7 days) and undergoing elective percutaneous coronary intervention (PCI) in a native coronary artery were randomized to receive a loading dose of rosuvastatin (n = 64) or not (n = 61). Blood samples were obtained before statin intake (time point A), 3 hours after medication (time point B), and 3 hours after PCI (time point C). The primary goal was the comparison in the variation of the serum inflammatory markers and their gene expression at the different time points between the two groups. Results. Baseline clinical, angiographic, and procedural characteristics did not significantly differ between the groups, except for the more frequent use of postdilation in the control group (73.4% vs 90.2%; P=.02). Patients pretreated with statin showed a reduction in the serum levels of interleukin (IL)-1 beta (Delta = -0.491 pg/mL; P-interaction<.001), IL-6 (Delta = -0.209 pg/mL; P-interaction<.001), and plasminogen activator inhibitor 1 (Delta = -1.573 pg/mL; P-interaction<.001) as well as in their genetic expression, which was not observed in the control group. Regarding high-sensitivity c-reactive protein, there was no significant variation in its value from time point A to C in patients pretreated with statin (P=.58) while it significantly increased in the control group ( P=.04). Conclusion. Among patients with stable coronary artery disease undergoing PCI with stents, pretreatment with high dose of rosuvastatin resulted in significant reduction in the serum levels of important inflammatory markers and their genetic expression. (AU)

• FAPESP's process: 12/22989-1 - Effects of rosuvastatin on the acute inflammatory response mediators IL-1, IL-6, IL-8, TNF-±, TGF-², MCP-1/CCL-2, PAI-1, C-reactive protein and nitric oxide after implantation of nonpharmacologic coronary stent
• Grantee: Alexandre Antônio Cunha Abizaid
• Support Opportunities: Regular Research Grants